Pfizer (PFE)

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.

It's a great time to "buy low."

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launc...

Pfizer's acquired and recently launched products generated strong growth last quarter.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you.

Look for names that tend to trade independently of the overall market, and don't be afraid to achieve some income growth.

GoodRx (GDRX) Q1 2026 Earnings Call Transcript

The competition is far behind.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Animal health company Zoetis (NYSE:ZTS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales only rose 1.9% year on year to $2.26 billion. The com...

Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil...

Is Pfizer a yield trap? No way.

Investors often move like lemmings in the short term, giving long-term investors an opportunity to buy great companies.

Novavax (NVAX) Q1 2026 Earnings Transcript

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 mill...

Global pharmaceutical company Pfizer (NYSE:PFE) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 5.4% year on year to $14.45 ...

Just because a dividend stock has suffered a significant stumble doesn't mean the setback is permanent. It doesn't even mean its dividend is in jeopardy.

Pfizer (PFE) Q1 2026 Earnings Transcript